The effect of the 7-valent conjugate vaccine (PCV7) on the incidence of pneumococcal infections world-wide

Reviews and Research in Medical Microbiology

Volumn 19, Issue 3, 2008, Pages 79-85

  Dobay, Orsolya ^a   Amyes, Sebastian Gb ^b   Nagy, Károly ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Pneumococcus; PVC 7; Replacement disease; Serotypes; Vaccination

Indexed keywords

CARRIER PROTEIN; LEVOFLOXACIN; PCV 7 VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ACUTE OTITIS MEDIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; EUROPE; GENETIC RESISTANCE; GROUPS BY AGE; HERD IMMUNITY; HUMAN; IMMUNE RESPONSE; INCIDENCE; NASOPHARYNX; OTITIS MEDIA; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEROTYPE; UNITED STATES; VACCINATION; VIRULENCE;

EID: 67649612798     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MRM.0b013e3283299fa8     Document Type: Review

References (52)

1. http://www.who.int/immunization-delivery/new-vaccines/ pneumo/en/.
2. Austrian R. A brief history of pneumococcal vaccines. Drugs Aging 1999; 15 (Suppl 1):1-10.
3. Obaro SK. The new pneumococcal vaccine. Clin Microbiol Infect 2002; 8:623-633.
4. Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin Microb Rev 2003; 16:308-318.
5. Clarke SC, Scott KJ, McChlery SM. Serotypes and sequence types of pneumococci causing invasive disease in Scotland prior to the introduction of pneumococcal conjugate polysaccharide vaccines. J Clin Microbiol 2004; 42:4449-4452.
6. Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaptation of the species. Int J Antimicrob Agents 2008. doi:10.1016/j.ijantimicag.2008.01.021.
7. Ledwith M. Pneumococcal conjugate vaccine. Curr Opin Pediatr 2001; 13:70-74.
8. de Lencastre H, Tomasz A. From ecological reservoir to disease: the nasopharynx, day-care centres and drug-resistant clones of Streptococcus pneumoniae. J Antimicrob Chemother 2002; 50: 75-81.
9. Klein DL. Pneumococcal disease and the role of conjugate vaccines. Microb Drug Resist 1999; 5:147-157.
10. Clarke SC. Control of pneumococcal disease in the United Kingdom: the start of a new era. J Med Microbiol 2006; 55:975-980.
11. van Oosten M, de Greeff S, Spanjaard L, Schouls LM. Introductionof pneumococcal conjugate vaccine into the Dutch national immunisation programme. Euro Surveill 2006; 11: 2968.
12. Vestrheim DF, Løvoll O, Aaberge IS, Caugant DA, Høiby EA, Bakke H, et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumo-coccal disease among children in Norway. Vaccine 2008 [Epub ahead of print].
13. www.wyeth.com/vaccines.
14. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use: part I. Clin Infect Dis 2000; 30:100-121.
15. www.gsk.com.
16. www.wyeth.com/ClinicalTrialListings.
17. Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease: United States, 1998-2003. MMWR Morbid Mortal Weekly Rep 2005; 54:893-897.
18. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005; 365:1139-1146.
19. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N, and the Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349:1341-1348.
20. www.wyeth.co.uk.
21. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002; 21:810-815.
22. Grijalva CG, Poehling KA, Nuorti JP, Zhu Y, Martin SW, Edwards KM, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 2006; 118:865-873.
23. McCaig LF, Besser RE, Hughes JM. Trends in antimicrobial prescribing rates for children and adolescents. J Am Med Assoc 2002; 287:3096-3102.
24. Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media [published correction appears in Pediatr Infect Dis J 2003; 22:163]. Pediatr Infect Dis J 2003; 22:10-16.
25. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344:403-409.
26. Block SL, Hedrick J, Harrison CJ, Tyler R, Smith A, Findlay R, et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 2004; 23:829-833.
27. Hanage WP, Huang SS, Lipsitch M, Bishop CJ, Godoy D, Pelton SI, et al. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the postheptavalent conjugate vaccine era. J Infect Dis 2007; 195:347-352.
28. Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, Kellenberg J, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007; 26:468-472.
29. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. J Am Med Assoc 2007; 297:1784-1792.
30. Beall B, McEllistrem MC, Gertz RE Jr, Wedel S, Boxrud DJ, Gonzalez AL, et al., and the Active Bacterial Core Surveillance Team. Pre and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 2006; 44:999-1017.
31. Brueggemann AB, Pai R, Crook DW, Beall B. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog 2007; 3:e168.
32. Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008; 46:174-182.
33. Wilson J, Hill R, Eastaway A. Impact of pneumococcal conjugate vaccine (PCV7) on invasive pneumococcal disease in Scotland. Poster P1754, European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2008, Barcelona, Spain.
34. de Roux A, Schmöele-Thoma B, Siber R, Hackell J, Kuhnke A, Ahlers N, et al. Comparison of pneumococcal conjugated polysaccharide and free polysaccharide vaccines in the elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46:1015-1023.
35. McGee L, McDougal L, Zhou J, Spratt BG, Tenover FC, George R, et al. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the Pneumococcal Molecular Epidemiology Network. J Clin Microbiol 2001; 39:2565-2571.
36. Moore MR, Gertz RE Jr, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008; 197:1016-1027.
37. Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. J Am Med Assoc 2007; 298:1772-1778.
38. Hwa Choi E, Hee Kim S, Wook Eun B, Jung Kim S, Hee Kim N, Lee J, et al. Streptococcus pneumoniae serotype 19A in children: South Korea. Emerg Infect Dis 2008; 14:275-281.
39. Dobay O,RozgonyiF, Hajdú E, NagyE, Knausz M, Amyes SGB. The relationship between serotypes and PFGE genotypes in isolates of Streptococcus pneumoniae from Hungary. Clin Microb Infect 2005; 11:673-676.
40. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneu-moniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 2007; 26:123-128.
41. Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Oral presentation S167 at 18th ECCMID, Barcelona, Spain, April 2008.
42. Pletz MW, McGee L, Jorgensen J, Beall B, Facklam RR, Whitney CG, et al. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother 2004; 48:3491-3497.
43. Centers for Disease Control and Prevention (CDC). Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae: Massachusetts, 2001-2006. MMWR Morbid Mortal Weekly Rep 2007; 56:1077-1080.
44. Trzciński K, Thompson CM, Lipsitch M. Single-step capsular transformation and acquisition of penicillin resistance in Streptococcus pneumoniae. J Bacteriol 2004; 186:3447-3452.
45. Haber M, Barskey A, Baughman W, Barker L, Whitney CG, Shaw KM, et al. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine 2007; 25:5390-5398.
46. Nunes S, Sá-Lea ̃o R, Pereira LC, de Lencastre H. Emergence of a serotype 1 Streptococcus pneumoniae lineage colonising healthy children in Portugal in the seven-valent conjugate vaccination era. Clin Microb Infect 2008; 14:82-84.
47. Bos JM, Rümke H, Welte R, Postma MJ. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. Clin Ther 2003; 25:2614-2630.
48. Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, et al. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV7) vaccine to the Norwegian childhood vaccination program. Vaccine 2006; 24:5690-5699.
49. Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneu-mococcal conjugate vaccination in England and Wales. Vaccine 2004; 22:4203-4214.
50. Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M. Costeffectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Eur J Health Econ 2008; 9:7-15.
51. Lopalco PL (Editorial team). Use of 7-valent pneumococcal conjugate vaccine in EU. Euro Surveill 2006; 11:pii=3092.
52. Marchetti M, Colombo GL. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy. Vaccine 2005; 23:4565-4576.